Post-Translational Methylation of Human RAD52 in Response to DNA Damage and Replication Stress

Vinorelbine). Pts were reevaluated in last week of CRT and discussed in the multidisciplinary board. Operable pts were then, randomized either to definitive CRT (arm A) or surgery (arm B). Pts in arm A received a riskadapted boost to 65/71 Gy at 2 Gy per fraction without break and concurrent Cisplatin/Vinorelbine. Mean lung dose was held below 18 Gy. Results:With 161 randomized from300 planned pts (1/2004-8/2012), the trial was closed after second planned interim analysis for slow accrual + futility. 246 pts (70 F/176 M; stages, 75 T1-3 N2 / 80 T4 N0-1/ 91 T4 N2 or T1-3N3; histology, 95 SCC / 107 ADC / 44 other) were enrolled from 5 centers. Fiveyear overall survival of all 246 enrolled pts was 34% and was 42% for the 161 randomized pts. Overall survival of the randomized pts was not different between arms (p > 0.25, log-rank test) and was significantly higher than the expected value of 25% at 5 years in arm A. Median follow-up was 78 mo. Progression-free survival at 3 and 5 years was 35 (25-46)% at both time points in armA, and 40% (29-50%) and 32% (22-43%) in armB (pZ 0.71, log-rank test). Freedom from isolated loco-regional recurrence as the first site of relapse (ffLR) was analyzed after central review of follow-up imaging and clinical data from the highest recruiting center covering 71% of all patients. Actuarial ffLR at 5 years were similar in both arms. Treatment-related mortality was 2.5% in patients from arm A and 6.2% in arm B. Conclusions: Progression free survival was encouraging with both treatment arms. Intensified definitive AHF-CRT following IND-C can result in high ffLR in pts with operable stage IIIA(N2)/selected IIIB NSCLC. Acknowledgment: Deutsche Krebshilfe: No 70-3070-Eb. Author Disclosure: M. Stuschke: E. Research Grant; Merck. C. Pottgen: H. Speakers Bureau; Roche. T. Gauler: K. Advisory Board; BristolMyers-Squibb. G. Friedel: None. S. Veit: None. V. Heinrich: None. S. Welter: None. W. Spengler: None. H. Schmidberger: None. D. LutkeBrintrup: None. N. Lehmann: None. K. Jockel: None. M. Schuler: None. G. Stamatis: None. W. Eberhardt: H. Speakers Bureau; Hexal, Bristol-Meyers-Squibb, Teva. K. Advisory Board; Roche, AstraZeneca, Pfizer, Boehringer, GlaxoSmithKline, Lilly, Bristol-Myers-Squibb, Novartis, Amgen, Teva.